Objectives: To evaluate the spectrum of activity and potency of LBM415, the first of the peptide deformylase inhibitor (PDFI) class to be developed for treatment of community-acquired respiratory tract infections and uncomplicated skin and soft tissue infections (uSSTI), against a large, contemporary international collection of targeted pathogens collected during 2003-2004. Methods: A total of 21 636 isolates were tested by reference broth microdilution methods as part of a longitudinal international antimicrobial resistance surveillance study. Characteristics of the organism collection included resistance to oxacillin among 35.0% of Staphylococcus aureus and 76.0% of coagulasenegative staphylococci (CoNS); resistance to penicillin (MIC ‡ 2 mg/L) among 18.0% of Streptococcus pneumoniae; vancomycin resistance among 20.0% of Enterococcus spp. and ampicillin resistance among 22.0% of Haemophilus influenzae.
Introduction
The emergence of resistance in the commonly occurring Gram-positive and Gram-negative bacterial pathogens to antimicrobial agents has become a significant medical crisis. 1, 2 The increased morbidity, mortality and healthcare costs in inpatient and outpatient settings have been directly attributed to this problem. 3, 4 The limited number of antimicrobial classes and the common occurrence of cross-resistance within and between classes reinforce the urgent need to identify new compounds with novel mechanisms of action.
Peptide deformylase (PDF), a highly conserved metalloproteinase, is required for protein maturation in bacteria. [5] [6] [7] [8] [9] [10] [11] [12] As a prerequisite for initiation of protein synthesis, formyltransferase (the product of the fmt gene) transfers a formyl group to the amino acid methionine. 5, 7, 12 Bacterial protein synthesis is then initiated by the transfer of the charged initiator f-met tRNA to the A site of the ribosome. During protein maturation, the formyl group is removed, catalysed by deformylase, the product of def gene. 5, 7, 12 This is followed by the action of methionine aminopeptidase (MAP), resulting in the removal of the amino-terminal methionine residue. [6] [7] [8] 11 If the formyl group is not removed, the MAP cannot function and this stage of post-translational protein modification is inhibited. The cellular pathways for PDF and MAP are essential, and inhibition results in cell death (slowing and eventually stopping cell growth). While a PDF homologue is present in eukaryotic cells, specifically within mitochondria, recent data suggest that the eubacterial and human mitochondrial PDF proteins have several distinguishing structural features which should permit specificity among inhibitors. 13 The natural PDF inhibitor (PDFI), actinonin, has been studied since 1962 for its ability to affect protein expression in a variety of Gram-positive and Gram-negative organisms, and only in recent years has the actual mechanism of action been more fully elucidated. 10, 14, 15 Upon exposure of bacteria to the agent, protein maturation is inhibited by the inability of PDF to deformylate the N-terminal methionine residue, ultimately resulting in bacteriostasis. Following the identification of the natural product actinonin, several novel synthetic PDFI candidates have recently been described. The PDFI NVP-PDF386 was tested against over 1000 clinical strains for potency and spectrum of activity. 16 Results show that NVP-PDF386 demonstrated excellent potency against Staphylococcus aureus (MIC 90 1 mg/L). It was 2-fold less active against Enterococcus spp. (MIC 90, 2 mg/L) but 2-fold more active for Streptococcus pneumoniae (MIC 90 0.5 mg/L). The NVP-PDF386 inhibited 75.0% of Haemophilus influenzae at 8 mg/L, as well as 92.0% of Gram-positive species tested. Inhibition of all Moraxella catarrhalis isolates occurred at 0.5 mg/L. Overall, NVP-PDF386 showed potent activity against staphylococci, streptococci, enterococci, M. catarrhalis and selected anaerobes with MIC values of £4 mg/L, 16 demonstrating the potential for this class in a variety of clinical indications.
LBM415 (previously known as NVP PDF-713) is one of the first of the PDFI class to advance to early phase clinical trials for the oral and parenteral treatment of respiratory tract and skin and soft tissue infections caused by susceptible Gram-positive and Gram-negative organisms. [17] [18] [19] [20] [21] Recent studies have described LBM415 quality control guidelines for both disc and broth microdilution methods for use in clinical trial testing; validations of commercially prepared in vitro testing products have also been described. 18, 20 
Materials and methods

Bacterial strains
The organism collection (21 636 
Results
Overall spectrum of activity and potency of LBM415 LBM415 displayed significant antimicrobial activity against the surveillance isolates tested (Table 1 ). For S. aureus, growth of >99.9% of isolates was inhibited at 2 mg/L, except for the one PDFI-resistant clinical isolate described below. Growth of viridans group and b-haemolytic streptococci, as well as M. catarrhalis, was inhibited by 2 mg/L of LBM415. >8 mg/L; 68.4% susceptible). Among oxacillin-resistant S. aureus, 100.0% of strains tested were susceptible to linezolid, quinupristin/dalfopristin and vancomycin (Table 2) . LBM415 displayed uniform activity with MIC 50 values of 0.5 mg/L and MIC 90 values of 1-2 mg/L against S. pneumoniae (regardless of penicillin susceptibility). Among the S. pneumoniae strains grouped by penicillin susceptibility a stepwise increase in resistance was evident for erythromycin, clindamycin and chloramphenicol (Table 2 ). Ceftriaxone was highly active against both penicillin-susceptible (99.9%) and penicillin-resistant S. pneumoniae (87.5%). One hundred percent of S. pneumoniae strains showed susceptibility towards quinupristin/dalfopristin, levofloxacin, rifampicin and vancomycin.
b-Haemolytic and viridans group streptococci were all inhibited by LBM415, with MIC 50 values of 0.5 and 0.12 mg/L, respectively, and MIC 90 values of 0.5 and 1 mg/L. Viridans group streptococci demonstrated more variability in resistance to comparator agents, except for linezolid and vancomycin, of which 100.0% of the strains were susceptible. The only drugs for which lower susceptibility rates of b-haemolytic streptococci were demonstrated included erythromycin and clindamycin (82.2% and 93.7%, respectively); ‡99.0% of the strains displayed susceptibility to all other comparators.
LBM415 was consistently active against vancomycinsusceptible and vancomycin-resistant E. faecalis (MIC 50 , 2 mg/ L and MIC 90 , 4 mg/L) and vancomycin-susceptible and vancomycin-resistant E. faecium (MIC 50 , 1 mg/L and MIC 90 , 2 mg/L). Vancomycin-resistant E. faecalis (18 strains) exhibited high susceptibility rates to ampicillin (96.6%) and linezolid (97.5%), whereas chloramphenicol (95.7%), quinupristin/ dalfopristin (95.1%) and linezolid (99.1%) showed the greatest activity among vancomycin-resistant E. faecium. LBM415 also displayed a broad range (£0.016-8 mg/L) of activity against a ; breakpoints used for M. catarrhalis are those specified for H. influenzae for comparative purposes. b Breakpoint criteria have not been identified by CLSI. remained susceptible to the majority of comparator drugs with ceftazidime and meropenem susceptibilities of 95.3%. Ticarcillin-clavulanic acid (79.1%) and tetracycline (95.2%) demonstrated the highest resistance rates. Comparator drugs exhibited variable susceptibility rates for S. maltophilia with minocycline (100.0%) and trimethoprim/sulfamethoxazole (97.4%) showing the highest activity, whereas meropenem (92.7% resistance), piperacillin (81.5%) and tetracycline (65.7%) were less potent.
Case report (PDFI-resistant strain of S. aureus) One S. aureus strain (02-6390D) was isolated from a 34-year-old patient hospitalized in the USA in 2004 who had experienced multiple fractures during a motor vehicle accident. This strain was repeatedly isolated from multiple sites (chest, blood and abdominal wounds) during an extended hospitalization. Several classes of antimicrobials (b-lactams, aminoglycosides and fluoroquinolones) were administered to the patient intermittently during this time. The strain was fully susceptible to 16 agents representing 10 antimicrobial classes, except for penicillin (MIC, 0.5 mg/L) and LBM415 ( ‡1024 mg/L). This represents the first high-level LBM415-resistant strain to be recovered from a clinical source. The strain was found to contain multiple sequence changes in genes relevant to the resistance phenotype (defB and fmt, Table 5 ). When compared with the PDFIsusceptible strain, the Fmt protein from the PDFI-resistant strain had an amino acid substitution (L101I) in a residue that is highly conserved in PDF proteins from many species (H. influenzae, Pseudomonas aeruginosa, Escherichia coli, S. aureus, E. faecalis, Staphylococcus epidermidis, but not S. pneumoniae or Bacillus subtilis). The substitution D195N was also found in the Fmt from the PDFI-resistant strain. In the susceptible strains, this is a functionally conserved residue (Asp or Glu) next to an absolutely conserved aspartic acid. S212N, a third Fmt amino acid substitution identified, is at a non-conserved residue that is found immediately after an absolutely conserved tryptophan. The fmt mutations resulting in these substitutions are consistent with the hypothesis that Fmt-bypass in S. aureus confers resistance to LBM415. However, the individual contributions of each substitution towards the PDFI resistance phenotype have not been examined.
An amino acid change was also detected in PDF (N171D), in the C-terminal tail of the protein (Table 5 ). This residue is not conserved among the PDFs across bacterial species. However, it is downstream from the metal binding region of the enzyme. 
Surveillance study of LBM415, a PDFI
No data have been previously published in describing the selection of mutants of S. aureus with alterations in the defB gene; therefore the individual contribution of this substitution to the PDFI resistance phenotype remains unknown.
Discussion
There is a critical need for the development of new antimicrobial compounds that inhibit novel bacterial targets owing to the rapid emergence of antimicrobial resistance. 1,2 Given these criteria, the inhibition of peptide deformylation has recently been investigated in the search for new antimicrobials.
14 N-formylmethionine is required for the initiation of prokaryotic polypeptide synthesis. [7] [8] [9] Following chain elongation, the PDF enzyme uses iron as a catalytic metal for amide bond hydrolysis to cleave the N-formylmethionine group. 6, 7, 9, 12 This exposes the Nterminal methionine to hydrolysis by MAP. When deformylation with PDF is interrupted, the MAP enzyme cannot perform its intended function. This alteration in post-translational protein modification inhibits cell growth, although the ultimate cause of cell death is unknown.
Similar to the activities of NVP-PDF386, this study and others have demonstrated the potential for LBM415 as an antimicrobial agent, particularly against pathogens important in communityacquired respiratory tract infections (CARTI) and uncomplicated skin and skin structure infections. 16, 17, 19 The level of activity reported here against a large international collection of isolates supports this with inhibition of ‡99.0% of all staphylococci, streptococci, E. faecium and M. catarrhalis at MIC £ 4 mg/L, as well as inhibition of 97.0% of E. faecalis and 92.0% of H. influenzae strains. This PDFI compound displays antimicrobial activity against a broad spectrum of pathogens and enhanced potency against the commonly occurring community pathogens, making it an attractive candidate for further clinical development. Interestingly, LBM415 retains activity against strains displaying the commonly occurring resistance phenotypes including resistance to oxacillin for staphylococci, penicillin resistance of pneumococci, vancomycin resistance of enterococci and ampicillin resistance of H. influenzae and M. catarrhalis, similar to published reports. 17, 19, [21] [22] [23] LBM415 is known to lack appreciable activity against the Enterobacteriaceae or P. aeruginosa. 17, 20 Aside from the activity against organisms associated with CARTI, LBM415 also exhibited promising activity Neisseria meningitidis. 26 This recent study tested LBM415 in vitro activity against 100 N. meningitidis and 157 N. gonorrhoeae clinical isolates. 26 The agent displayed acceptable activity against N. meningitidis with an MIC 50 of 1 mg/L and MIC 90 of 2 mg/L; all isolates were inhibited by 4 mg/L. Unfortunately, potency levels were lower for N. gonorrhoeae by 4-fold (MIC 50 , 4 mg/L and MIC 90 , 8 mg/L). One gonococcal strain exhibited high-level PDFI resistance with an MIC of >16 mg/L. 26 The maturation of certain proteins following translation is essential for bacterial survival. Key components of the protein maturation process include PDF (encoded by defB) and formyltransferase (encoded by fmt).
8,14,17 LBM415 specifically inhibits PDF activity. Spontaneous resistance to PDFIs has been documented in vitro and is associated with the selection of mutants with alterations in one of these genes. Margolis et al. 27 ,28 demonstrated that defB mutations in S. pneumoniae result in amino acid substitutions close to conserved domains involved in the binding of the substrate which are critical to PDF activity. Further study also showed that PDFI-resistant mutants of E. coli and S. aureus lack formyltransferase activity, which bypasses the need for deformylase activity. 27 ,28 When E. coli or S. aureus mutants with fmt alterations are selected, the mutations often impose a fitness cost on the cell and published accounts of in vivo infection models demonstrate that these mutants are less virulent than the PDFI-sensitive parental strains. 27 The single LBM415-resistant S. aureus isolate recovered from a clinical specimen was the first observation of a clinical strain that is fully resistant to PDFIs. Sequence analysis revealed multiple missense mutations in fmt. In a laboratory setting, singlestep loss of function mutations in fmt are typically selected in S. aureus exposed to PDFIs. The PDFI-resistant clinical S. aureus strain also harboured a single nucleotide change in defB, resulting in a single amino acid substitution in PDF. There are no previously reported data describing the selection for mutations in S. aureus defB upon exposure to a PDFI in the laboratory setting. The contribution of the defB mutation to the resistance profile of this strain remains unknown.
PDFIs are a novel class of bacteriostatic agents being developed for the treatment of infections in the community setting. 5, 7, 17, 20 LBM415 demonstrates antimicrobial activity against the common Gram-positive pathogens, including resistant subsets, with no apparent differences in potency against strains from diverse geographical regions. The majority of Gramnegative fastidious species (H. influenzae, M. catarrhalis) were also inhibited by LBM415 although other Gram-negative species (Enterobacteriaceae and P. aeruginosa) are not within the antimicrobial spectrum of this agent. As a class of antimicrobials, the PDFI compounds exhibit a spectrum of activity and unique mode of action that promises to be a significant advance in chemotherapy targeting infections of the respiratory tract and skin and soft tissues. The examination of additional candidate compounds to optimize antimicrobial spectrum and potency remains warranted.
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